Rucaparib shows clinical benefit for pancreatic cancer

New Delhi : The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M Domchek, executive director of the Basser Centre for BRCA at the Abramson Cancer Centre of the University of Pennsylvania, at the American Society of Clinical Oncology (ASCO) Annual Meeting. Overall, a clinical benefit was observed in 32 per cent of patients (6 of 19) treated with rucaparib. Of the 19 pancreatic patients, one had a complete response and two had partial responses, while four patients had stable disease. The objective response rate, the primary endpoint for the study, was 16 per cent (3 of 19). These results are encouraging and further demonstrate the clinical significance of the BRCA cancer genes outside of breast and ovarian, and not just in women," Domchek said. Importantly, it points us to a potential new treatment avenue for pancreatic cancer, an aggressive disease that's often caught in the later stages. Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.
" Earlier this year, the American Cancer Society reported that it is estimated that in 2016, nearly 42,000 people will die from the disease, surpassing the number of deaths from breast cancer by more than 1,000.
Recent studies have shown that rucaparib, a PARP inhibitor, effectively treats patients with platinum-sensitive, relapsed, high-grade ovarian cancer harbouring a BRCA mutation.
In a study presented at ASCO in 2015, researchers showed that treatment resulted in a 69 per cent RECIST response rate in these patients.
In April 2015, it received a US Food and Drug Administration (FDA) Breakthrough Therapy designation.
The FDA's designation, created in 2012, is intended to expedite the development and review of new medicines - both drugs and biologic agents - that treat serious or life-threatening conditions, if the therapy has demonstrated substantial improvement over available therapies. The success in ovarian patients prompted a clinical study in pancreatic patients with the same mutation--about nine per cent of pancreatic patients are BRCA1/BRCA2 positive.
The disease control rate (defined as partial response or stable disease for more than 12 weeks) for all patients was 32 per cent (6 of the 19 patients) and 50 per cent (three of six patients) in patients who received one prior line of chemotherapy. All patients who responded received only one prior line of chemotherapy therapy, suggesting that the drug may be an option earlier in the treatment course.

Share it